{"id":"menbvac","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain/erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant meningococcal B surface proteins that trigger both humoral and cellular immune responses. This leads to the generation of protective antibodies and memory B cells that can recognize and neutralize the pathogen upon natural exposure, preventing invasive meningococcal disease.","oneSentence":"MenBvac is a meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:41.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B"}]},"trialDetails":[{"nctId":"NCT00197795","phase":"PHASE2","title":"Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults","status":"COMPLETED","sponsor":"Public Health England","startDate":"2005-01","conditions":"Neisseria Meningitidis","enrollment":30},{"nctId":"NCT01565577","phase":"PHASE3","title":"Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2012-04","conditions":"Vaccination With MenbVac","enrollment":117},{"nctId":"NCT01621945","phase":"","title":"Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2012-04","conditions":"Neisseria Meningitidis","enrollment":120},{"nctId":"NCT00450554","phase":"","title":"Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2007-02","conditions":"Vaccination","enrollment":236},{"nctId":"NCT01054053","phase":"","title":"Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2009-04","conditions":"Vaccination","enrollment":218}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MenBvac","genericName":"MenBvac","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenBvac is a meningococcal B vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}